首页> 美国卫生研究院文献>ERJ Open >Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support
【2h】

Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support

机译:评估数字医疗技术对结核病治疗支持的潜在成本和影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ensuring adherence and support during treatment of tuberculosis (TB) is a major public health challenge. Digital health technologies could help improve treatment outcomes. We considered their potential cost and impact on treatment for active or latent TB in Brazil.Decision analysis models simulated two adult cohorts with 1) drug-susceptible active TB, and 2) multidrug-resistant TB, and two cohorts treated with isoniazid for latent TB infection (LTBI): 1) close contacts of persons with active TB, and 2) others newly diagnosed with LTBI. We evaluated four digital support strategies: two different medication monitors, synchronous video-observed therapy (VOT), and two-way short message service (SMS). Comparators were standard directly observed treatment for active TB and self-administered treatment for LTBI. Projected outcomes included costs (2016 US dollars), plus active TB cases and disability-adjusted life years averted among persons with LTBI.For individuals with active TB, medication monitors and VOT are projected to lead to substantial (up to 58%) cost savings, in addition to alleviating inconvenience and cost to patients of supervised treatment visits. For LTBI treatment, SMS and medication monitors are projected to be the most cost-effective interventions. However, all projections are limited by the scarcity of published estimates of clinical effect for the digital technologies.
机译:确保结核病(TB)治疗期间的依从性和支持是一项重大的公共卫生挑战。数字医疗技术可以帮助改善治疗效果。决策分析模型模拟了两个成人队列,其中1个是药物敏感性活动性TB,另外2个是多药耐药性TB,另外两个队列是用异烟肼治疗的潜在TB。感染(LTBI):1)活动性结核病患者的密切接触,以及2)新诊断为LTBI的其他人。我们评估了四种数字支持策略:两个不同的药物监控器,同步视频观察疗法(VOT)和双向短信服务(SMS)。比较者是活动性结核病的标准直接观察治疗和LTBI的自我管理治疗。预计的结局包括成本(2016年美元),加上活动性结核病例和LTBI患者避免的残疾调整生命年。对于活动性结核患者,药物监控器和VOT预计将节省大量成本(最多58%) ,除了减轻监督治疗就诊给患者带来的不便和成本。对于LTBI治疗,SMS和药物监测仪预计将是最具成本效益的干预措施。但是,所有预测都受到数字技术临床效果公开评估的缺乏的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号